Therapeutic Targets Database
BIDD Pharmainformatics Databases
 
   
 

 

Target Validation Information
TTD IDTTDS00393
Target NameMelatonin receptor type 1A    
Type of TargetSuccessful target    
Drug Potency against TargetRamelteonKi = 0.014 nM[1]
RamelteonKi = 14 nM[2]
AgomelatineIC50 = 0.062 nM[1]
LY-156735IC50 = 0.081 nM[1]
N-(2-(5-methoxybenzofuran-3-yl)ethyl)acetamideIC50 = 0.6 nM[3]
5-methoxycarbonylamino-N-acetyltryptamineIC50 = 100 nM[3]
4-(4-butylpiperidin-1-yl)-1-o-tolylbutan-1-oneKi < 1000 nM[4]
IODOMELATONINKi = 0.013 nM[5]
beta,beta-dimethylmelatoninKi = 1.12 nM[6]
UCM-454Ki = 1.4 nM[7]
beta-methylmelatoninKi = 1.67 nM[6]
N-(3-(2,5-dimethoxyphenyl)propyl)acetamideKi = 1280 nM[8]
N-[2-(5-Hydroxy-1H-indol-3-yl)-ethyl]-acetamideKi = 1640 nM[9]
N-(3-(2-ethoxy-5-methoxyphenyl)propyl)acetamideKi = 183 nM[8]
N-(2,3-Dihydro-1H-phenalen-2-yl)-acetamideKi = 195 nM[9]
N-(3-(3-methoxyphenyl)propyl)acetamideKi = 23.3 nM[8]
N-(3-(3-methoxyphenyl)-3-phenylallyl)acetamideKi = 230 nM[7]
N-(3-(4-hydroxy-3-methoxyphenyl)propyl)acetamideKi = 257 nM[8]
N-(3-(2-hydroxy-5-methoxyphenyl)propyl)acetamideKi = 379 nM[8]
N-(3-(5-methoxy-2-propoxyphenyl)propyl)acetamideKi = 400 nM[8]
N-(2,3,4,9-Tetrahydro-1H-carbazol-3-yl)-acetamideKi = 5350 nM[10]
N-(3-(3-methoxyphenyl)propyl)propionamideKi = 85.4 nM[8]
Ref 1Curr Top Med Chem. 2008;8(11):954-68.Melatonin receptor agonists: SAR and applications to the treatment of sleep-wake disorders. To Reference
Ref 2Trends Pharmacol Sci. 2001 Aug;22(8):409-14.Therapeutic opportunities from muscarinic receptor research. To Reference
Ref 3Bioorg Med Chem. 2008 May 1;16(9):4954-62. Epub 2008 Mar 17.Design and synthesis of benzofuranic derivatives as new ligands at the melatonin-binding site MT3. To Reference
Ref 4J Med Chem. 2010 Sep 9;53(17):6386-97.Discovery of N-{1-[3-(3-oxo-2,3-dihydrobenzo[1,4]oxazin-4-yl)propyl]piperidin-4-yl}-2-phenylacetamide (Lu AE51090): an allosteric muscarinic M1 receptor agonist with unprecedented selectivity and procognitive potential. To Reference
Ref 5J Med Chem. 2002 Apr 25;45(9):1853-9.Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3). To Reference
Ref 6J Med Chem. 2006 Jun 15;49(12):3509-19.Mapping the melatonin receptor. 7. Subtype selective ligands based on beta-substituted N-acyl-5-methoxytryptamines and beta-substituted N-acyl-5-methoxy-1-methyltryptamines. To Reference
Ref 7J Med Chem. 2009 Feb 12;52(3):826-33.2-[(2,3-dihydro-1H-indol-1-yl)methyl]melatonin analogues: a novel class of MT2-selective melatonin receptor antagonists. To Reference
Ref 8Bioorg Med Chem Lett. 2010 Apr 15;20(8):2582-5. Epub 2010 Feb 25.Synthesis of substituted N-[3-(3-methoxyphenyl)propyl] amides as highly potent MT(2)-selective melatonin ligands. To Reference
Ref 9J Med Chem. 1996 Aug 2;39(16):3089-95.Synthesis of 2-amido-2,3-dihydro-1H-phenalene derivatives as new conformationally restricted ligands for melatonin receptors. To Reference
Ref 10Bioorg. Med. Chem. Lett. 4(13):1559-1564 (1994) To Reference



 

Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.


Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore


All rights reserved.

 
   
           
 
Computer-aided Drug Design
About BIDD | Databases | Software | Teaching | Research |  Links

Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543